Fusco et al. studied 10 patients with prolactinomas and found that BIM23206, a SRL selective for SST5, could inhibit PRL in a dose-dependent manner similar to cabergoline in DA-sensitive prolactinomas but only partially suppressed PRL secretion in DA-resistant prolactinomas. This evidence concerns the gene PRL and prolactin-producing pituitary gland adenoma.